medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 4

<< Back Next >>

Ann Hepatol 2013; 12 (4)

Predicting the prognosis in acute liver failure: results from a retrospective pilot study using the LiMAx test

Friso LJ, Nihad KA , Malinowski M, Schulz A, Jara M, Neuhaus P, Stockmann M

Language: English
References: 25
Page: 388-394
PDF size: 150.44 Kb.


ABSTRACT

Background. Acute liver failure (ALF) is a rare but potentially life-threatening condition and liver transplantation (LTX) remains frequently the only effective therapy. Nevertheless, some patients recover without LTX but the individual indication for or against LTX remains difficult. Aim. To evaluate maximal liver function capacity (LiMAx) for predicting the prognosis of ALF. Material and methods. Clinic data of 12 patients was retrospectively analyzed to compare the different liver function test results with the patients’ clinical outcome. Patients were assessed by the LiMAx test, a non-invasive breath test determining cytochrome P450 1A2 capacity using intravenous 13C-methacetin. Statistical analysis compared patients with spontaneous recovery versus non-recovery (LTX or death). Results. Twelve patients (6 male, 6 female; 49 [11-72] years) with viral hepatitis (n = 2), toxic liver injury (n = 3), or cryptogenic liver failure (n = 7) were analyzed. Seven patients fully recovered from ALF and were discharged without LTX. Three patients died and two underwent LTX. The King’s College Criteria (KCC) was fulfilled in only one out of five patients without recovery. The LiMAx was 19 ± 19 (16-62) for non-recovery vs. 94 ± 119 (39-378) µ g/kg/h for recovery (P = 0.018). In contrast, all biochemical parameters [bilirubin (P = 0.106), creatinine (P = 0.343), AST (P = 0.53), ALT (P = 0.876) and INR (P = 0.876) were statistically indistinct. Also the Model for End-Stage Liver Disease (MELD) score did not show a difference [35 ± 4.3 (29-40) vs. 30 ± 11.5 (6-40); P = 0.27]. Conclusions. Maximal liver function capacity determined by LiMAx test is severely impaired in patients with ALF. The LiMAx test might be effective in predicting the individual prognosis and the need for LTX in ALF.


REFERENCES

  1. Bernal W, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010; 376: 190-201.

  2. Trey C, Davidson CS. The management of fulminant hepatic failure. Progress in liver diseases 1970; 3: 282-98.

  3. Liou IW, Larson AM. Role of liver transplantation in acute liver failure. Semin Liver Dis 2008; 28: 201-9.

  4. Polson J. Assessment of prognosis in acute liver failure. Semin Liver Dis 2008; 28: 218-25.

  5. Merle U, Sieg O, Stremmel W, Encke J, Eisenbach C. Sensitivity and specificity of plasma disappearance rate of indocyanine green as a prognostic indicator in acute liver failure. BMC gastroenterology 2009; 9: 91.

  6. Du WB, Pan XP, Li LJ. Prognostic models for acute liver failure. Hepatobiliary Pancreat Dis Int 2010; 9: 122-8.

  7. Nakayama N, Oketani M, Kawamura Y, Inao M, Nagoshi S, Fujiwara K, Tsubouchi H, et al. Algorithm to determine the outcome of patients with acute liver failure: a data-mining analysis using decision trees. J Gastroenterol 2012.

  8. Kumar R, Shalimar, Sharma H, Goyal R, Kumar A, Khanal S, Prakash S, et al. Prospective derivation and validation of early dynamic model for predicting outcome in patients with acute liver failure. Gut 2012; 61: 1068-75.

  9. Naiki T, Nakayama N, Mochida S, Oketani M, Takikawa Y, Suzuki K, Tada SI, et al. Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: Application to indication criteria for liver transplantation. Hepatol Res 2012; 42: 68-75.

  10. O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-45.

  11. Anand AC, Nightingale P, Neuberger JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King’s criteria. J Hepatol 1997; 26: 62-8.

  12. McPhail MJ, Wendon JA, Bernal W. Meta-analysis of performance of Kings’s College Hospital Criteria in prediction of outcome in non-paracetamol-induced acute liver failure. J Hepatol 2010; 53: 492-9.

  13. Stockmann M, Lock JF, Riecke B, Heyne K, Martus P, Fricke M, Lehmann S, et al. Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg 2009; 250: 119- 25.

  14. Lock JF, Schwabauer E, Martus P, Videv N, Pratschke J, Malinowski M, Neuhaus P, et al. Early diagnosis of primary nonfunction and indication for reoperation after liver transplantation. Liver Transpl 2010; 16: 172-80.

  15. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.

  16. Stockmann M, Lock JF, Malinowski M, Seehofer D, Puhl G, Pratschke J, Neuhaus P. How to define initial poor graft function after liver transplantation? - a new functional definition by the LiMAx test. Transpl Int 2010; 23: 1023-32.

  17. Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003; 31: 299-305.

  18. Bernal W, Wendon J, Rela M, Heaton N, Williams R. Use and outcome of liver transplantation in acetaminophen-induced acute liver failure. Hepatology 1998; 27: 1050-5.

  19. Kremers WK, van IJperen M, Kim WR, Freeman RB, Harper AM, Kamath PS, Wiesner RH. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004; 39: 764-9.

  20. Hadem J, Tacke F, Bruns T, Langgartner J, Strnad P, Denk GU, Fikatas P, et al. Etiologies and Outcomes of Acute Liver Failure in Germany. Clin Gastroenterol Hepatol 2012.

  21. Katoonizadeh A, Decaestecker J, Wilmer A, Aerts R, Verslype C, Vansteenbergen W, Yap P, et al. MELD score to predict outcome in adult patients with non-acetaminophen- induced acute liver failure. Liver Int 2007; 27: 329-34.

  22. Cholongitas E, Theocharidou E, Vasianopoulou P, Betrosian A, Shaw S, Patch D, O’Beirne J, et al. Comparison of the sequential organ failure assessment score with the King’s College Hospital criteria and the model for end-stage liver disease score for the prognosis of acetaminophen-induced acute liver failure. Liver Transpl 2012; 18: 405-12.

  23. Schmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007; 45: 789-96.

  24. Zaman MB, Hoti E, Qasim A, Maguire D, McCormick PA, Hegarty JE, Geoghegan JG, et al. MELD score as a prognostic model for listing acute liver failure patients for liver transplantation. Transplant Proc 2006; 38: 2097-8.

  25. Pelaez-Luna M, Martinez-Salgado J, Olivera-Martinez MA. Utility of the MAYO End-Stage Liver Disease score, King’s College Criteria, and a new in-hospital mortality score in the prognosis of in-hospital mortality in acute liver failure. Transplant Proc 2006; 38: 927-9.




2020     |     www.medigraphic.com